ArticlePregnancy (Hoboken, N.J.)2026
Utility of ultrasound surveillance of fetal growth in patients with marginal or velamentous cord insertion.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Abnormal cord insertion into the placenta (marginal and velamentous) has been associated with fetal growth restriction (FGR), leading some to recommend evaluation of fetal growth in the third trimester. The purpose of this study was to evaluate the timing of ultrasound surveillance in patients with marginal cord insertion (MCI) or velamentous cord insertion (VCI). Methods: Retrospective cohort of singleton pregnancies diagnosed with isolated MCI or VCI prior to 24 weeks at a single center from September 2021 to May 2025. Outcomes considered were diagnosis of FGR (estimated fetal weight [EFW] or abdominal circumference [AC] <10 percentile) and oligohydramnios (amniotic fluid index [AFI] ≤ 5 cm). The number of ultrasound scans needed to identify one abnormality (NNS) and 95% confidence interval (CI) were calculated for scans performed at 24+0-31+6 weeks and ≥ 32 weeks. Results: Among 248 patients with MCI meeting inclusion criteria, 710 ultrasounds were performed ≥ 24 weeks. A total of eight (3.2%) cases of FGR were diagnosed. Prior to 32 weeks, four cases of FGR were diagnosed (NNS 37.2, 95% CI, 14.9-135.8); however, half of these resolved on follow-up ultrasound. After 32 weeks, the NNS to identify one case of FGR was 80.5 (95% CI, 31.7-294.6); FGR persisted on subsequent ultrasound(s) for all of these cases. Among 65 patients with VCI meeting inclusion criteria, 151 ultrasounds were performed. Two cases of FGR were diagnosed, both ≤ 32 weeks. The NNS to diagnose one case from 24+0-31+6 weeks was 26.5 (95% CI, 7.7-217.2). There were no cases of oligohydramnios diagnosed in either sample. Conclusion: For patients with MCI, half of FGR cases diagnosed ≤32 weeks resolved prior to delivery and were thus likely false-positives, while all cases of FGR diagnosed ≥32 weeks persisted; thus, a single ultrasound at 32-36 weeks may be considered as a resource-efficient monitoring approach. Among patients with VCI, both FGR cases (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.